Asthma – Geographic Focus: China – China In-Depth – Asthma
Asthma is a common chronic airway disease that affects children and adults. The asthma therapy market in China consists of many well-established agents, including inhaled agents (GSK’s Advair / Seretide, AstraZeneca’s Symbicort), oral drugs (montelukast), and biologics (Roche / Novartis’s Xolair). Current treatments fulfill the efficacy needs of the majority of patients with asthma, but unmet need remains high in the treatment of severe asthma. Novel targeted therapies—benralizumab (AstraZeneca’s Fasenra), mepolizumab (GSK’s Nucala), and Tezepelumab (AstraZeneca’s Tezspire)—are in late-phase development in China for moderate to severe asthma. The launch and uptake of these agents will lead to significant growth of China’s asthma therapy market over 2023-2033. This report provides a comprehensive analysis of the asthma market in China, including current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.
QUESTIONS ANSWERED
- How large is China’s drug-treatable pool, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs and why? What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of asthma in China?
- What are the key market access considerations, and how will they impact the uptake of emerging therapies for asthma in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Release date
September 2024
Geography
China
Primary research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 pulmonologists.
Epidemiology
Diagnosed prevalence of asthma in China, with urban and rural breakup. Clinically- and market-relevant drug-treatable populations.
Forecast
10-year, annualized, drug-level sales and patient share of key asthma therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies
Phase 3/PR: 5+ drugs; Phase 2: 10+ drugs.
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
